Tramadol / Magnesium in Ropivacaine Solution in UG-bilateral TAP Block and Analgesia in Robotic Radical Prostatectomy
Enrolling by invitationNot applicableNCT07289321
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Tramadol and magnesium have already been researched in recent decades for their different roles in pain control. This clinical study will compare and re-evaluate their effect on the duration and quality of analgesia provided by a regional anesthesia technique. Participants will be men aged 40 to 80 years with prostate cancer who are scheduled for robot-assisted radical prostatectomy. Initially, all patients will receive general anesthesia and will then be randomly divided into three groups of 35 patients each to undergo bilateral transverse abdominal plane (TAP) block under aseptic conditions. This involves insertion of a needle into the plane between the internal oblique and transverse abdominal muscles under ultrasound guidance in order to inject the local anesthetic solution, as the responsible nerves run through the muscles of the abdominal wall. Specifically, 35 patients will receive only local anesthetic (ropivacaine), 35 will receive ropivacaine plus tramadol, and 35 will receive ropivacaine plus magnesium. Neither the researchers nor the participants will be aware of the composition of the solution administered (double-blind randomized controlled trial). The two co-primary endpoints are: (1) intraoperative fentanyl consumption, guided by the Nociception Level (NOL) index, and (2) postoperative pain intensity assessed by the Numeric Rating Scale (NRS, 0-10) at 8 time points within the first 24 hours (at 5, 15, 30, and 60 minutes in the Post-Anesthesia Care Unit and at 2, 4, 8, and 24 hours on the ward, both at rest and on coughing), analysed by global repeated measures ANOVA. Secondary endpoints include total rescue tramadol consumption and time to first rescue dose in the first 24 postoperative hours, sedation level assessed by the Ramsay Sedation Scale and peripheral oxygen saturation (SpO₂) as safety parameters, and the incidence of postoperative nausea and vomiting (PONV). In addition, researchers will contact participants at 1, 3, and 6 months postoperat…
Study details
- Official title
- Effect of Tramadol or Magnesium in Local Anesthetic Solution on Ultrasound-guided Bilateral TAP Block During Robotic Radical Prostatectomy on Acute Perioperative Pain and Chronic Postoperative Pain.
- Conditions
- Perioperative Pain in Robotic Prostatectomy
- Interventions
- Other: Ultrasound - guided bilateral transversus abdominis plane block (TAP) in patients undergoing robotic-assisted radical prostatectomy.
- Sponsor
- Aretaieion University Hospital
- Start date
- 2025-12-09
- Primary completion
- 2028-12-10
- Sex
- Male
- Age range
- from 40 Years to 80 Years
- Results posted
- No results posted in this snapshot
- Countries
- Greece
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * males * age 40-80 years * physical status I-III according to the American Society of Anesthesiologists (ASA physical status) * undergoing robotic-assisted radical prostatectomy using Da Vinci Xi. Exclusion Criteria: * Patients allergic to ropivacaine, tramadol, magnesium, or other drugs used in the study * with coagulation disorders due to disease or medication, * inflammation at the site of the block, * addiction to alcohol * history of opioid tolerance * patients unable to complete the pain assessment scale * patients unable or unwilling to provide written consent to participate in the study.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07289321